Gary W. Pace - 14 Jul 2026 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)

Reporting relationship: Director
Issuer ticker: CRDF
Reported as of: 14 Jul 2026
Net transaction value: +$1,000,000
SEC form: 4
Accepted by SEC: 16 Jul 2026, 16:03:02 UTC
Prior SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Gary Pace

Key filing fact

Gary W. Pace filed Form 4 for Cardiff Oncology, Inc. (CRDF) on 16 Jul 2026.

Key facts

This page summarizes Gary W. Pace's Form 4 filing for Cardiff Oncology, Inc. (CRDF).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jul 2026, 16:03.

Change

Previous filing in this sequence was filed on 22 Jun 2026.
Current net transaction value: +$1,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001184778 Primary reporting owner

PACE GARY W

Relationship: Director
Address: C/O CARDIFF ONCOLOGY, INC., 11055 FLINTKOTE AVENUE, SAN DIEGO
Signature: /s/ Gary Pace
Signature date: 16 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRDF transaction

Common Stock

Purchase

Transaction value: $1,000,000
Shares: +687,285
Change %: +51%
Price: $1.46
Shares after: 2,043,661
Date: 14 Jul 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRDF transaction Derivative

Common Stock Purchase Warrant

Purchase

Transaction value
Shares: +687,285
Change %
Price: $0.000000^*
Shares after: 687,285
Date: 14 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 687,285
Exercise price: $1.33
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders.

Footnote F2

The term of exercise is equal to five and one-half years after the Initial Exercise Date.